ATE293169T1 - Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen - Google Patents

Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen

Info

Publication number
ATE293169T1
ATE293169T1 AT02729440T AT02729440T ATE293169T1 AT E293169 T1 ATE293169 T1 AT E293169T1 AT 02729440 T AT02729440 T AT 02729440T AT 02729440 T AT02729440 T AT 02729440T AT E293169 T1 ATE293169 T1 AT E293169T1
Authority
AT
Austria
Prior art keywords
latency
pharmaceutically active
fusion protein
nucleic acid
construct
Prior art date
Application number
AT02729440T
Other languages
English (en)
Inventor
Yuti Chernajovsky
Hanna Stina Dreja
Gillian Adams
Original Assignee
Queen Mary & Westfield College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary & Westfield College filed Critical Queen Mary & Westfield College
Application granted granted Critical
Publication of ATE293169T1 publication Critical patent/ATE293169T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02729440T 2001-01-09 2002-01-09 Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen ATE293169T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0100551.1A GB0100551D0 (en) 2001-01-09 2001-01-09 Protein
US09/756,283 US6942853B2 (en) 2001-01-09 2001-01-09 Latent fusion protein
PCT/GB2002/000068 WO2002055098A2 (en) 2001-01-09 2002-01-09 Latency associated peptide for providing latency to pharmaceutically active proteins

Publications (1)

Publication Number Publication Date
ATE293169T1 true ATE293169T1 (de) 2005-04-15

Family

ID=26245544

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02729440T ATE293169T1 (de) 2001-01-09 2002-01-09 Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen

Country Status (10)

Country Link
US (1) US6942853B2 (de)
EP (1) EP1349944B1 (de)
JP (1) JP4201253B2 (de)
AT (1) ATE293169T1 (de)
AU (1) AU2002219345B2 (de)
DE (1) DE60203692T2 (de)
DK (1) DK1349944T3 (de)
ES (1) ES2240740T3 (de)
GB (1) GB0100551D0 (de)
WO (1) WO2002055098A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
CN101044154A (zh) * 2002-02-14 2007-09-26 威廉·J·鲁特 治疗宿主中切割的嵌合分子
AU2006302587A1 (en) * 2005-10-04 2007-04-19 Greenville Hospital System Latent procytotoxins and uses thereof
DE102006009324A1 (de) 2006-03-01 2007-09-06 Dr.Ing.H.C. F. Porsche Ag Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
GB0724556D0 (en) * 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
FR2932190A1 (fr) * 2008-06-10 2009-12-11 Commissariat Energie Atomique Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
GB0911365D0 (en) 2009-06-30 2009-08-12 Bioceramic Therapeutics Ltd Multicomponent glasses for use as coatings and in personal care products
WO2011123683A2 (en) * 2010-04-02 2011-10-06 University Of Rochester Protease activated cytokines
EP2878308B1 (de) * 2013-12-02 2018-10-31 Thomas Harder Mittel und Verfahren zur Unterdrückung der T-Zell-Aktivierung
GB201411506D0 (en) 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
WO2019222294A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
BR112021005907A2 (pt) 2018-09-27 2021-08-10 Xilio Development, Inc. citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
ES2780274A1 (es) * 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
KR20220101147A (ko) 2019-11-14 2022-07-19 웨어울프 세라퓨틱스, 인크. 활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct
EP4133085A1 (de) 2020-04-10 2023-02-15 CytomX Therapeutics, Inc. Aktivierbare cytokinkonstrukte und verwandte zusammensetzungen und verfahren
EP4308594A2 (de) 2021-03-16 2024-01-24 CytomX Therapeutics, Inc. Maskierte aktivierbare cytokinkonstrukte und verwandte zusammensetzungen und verfahren

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284763A (en) * 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
CA2003886A1 (en) 1988-12-16 1990-06-16 Anthony F. Purchio Cloning and expression of simian transforming growth factor-beta 1
ES2083469T3 (es) 1989-11-22 1996-04-16 Genentech Inc Peptido asociado a una latencia y utilizaciones del mismo.
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
KR100227406B1 (ko) 1993-05-12 1999-12-01 브루스 엠. 에이센 Bmp-11 조성물
CA2712304C (en) 1994-06-10 2011-10-25 United States Surgical Corporation Recombinant chimeric proteins and methods of use thereof
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
WO1997012048A1 (en) * 1995-09-27 1997-04-03 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
DE19701141C1 (de) 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
EP0977862B8 (de) * 1997-04-30 2009-09-16 Twinstrand Therapeutics Inc. Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen
GB2324960A (en) 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
JP2004508838A (ja) * 2000-09-11 2004-03-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 組合せ蛍光エネルギー移動タグ及びそれらの使用

Also Published As

Publication number Publication date
US6942853B2 (en) 2005-09-13
US20020151478A1 (en) 2002-10-17
EP1349944B1 (de) 2005-04-13
DE60203692T2 (de) 2006-03-02
GB0100551D0 (en) 2001-02-21
JP4201253B2 (ja) 2008-12-24
EP1349944A2 (de) 2003-10-08
AU2002219345B2 (en) 2006-03-16
JP2004520031A (ja) 2004-07-08
ES2240740T3 (es) 2005-10-16
WO2002055098A3 (en) 2002-11-21
DK1349944T3 (da) 2005-07-25
DE60203692D1 (de) 2005-05-19
WO2002055098A2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
ATE500323T1 (de) Subtilisin-variante
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
AR008727A1 (es) COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
WO2002014358A3 (en) Novel secreted proteins and their uses
BR9814276A (pt) Antìgenos de superfìcie
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
DK1904529T3 (da) Anvendelse af Stefin A som et scaffoldprotein
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
WO2004054607A3 (de) Stabile therapeutische proteine
AU2003222717A8 (en) Streptavidin-binding peptide
DE69941433D1 (de) Von protease typ ii spaltbares peptid
WO2002022662A3 (en) Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor
WO2003082897A3 (en) Synthetic active peptide fragments
ATE278011T1 (de) Human dnase ii
ATE281522T1 (de) Sentrin-spezifische menschliche protease senp1
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2004053117A3 (en) Serine protease
ATE427355T1 (de) Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna
TH62241A (th) ไบคูนินของคน
DE60129228D1 (de) Humane 7-transmembranproteine und dafür codierende polynukleotide
WO2002000709A3 (en) Cerebellin homologous polypeptides and therapeutic uses thereof
WO2003031463A3 (en) 14081, a human trypsin-like serine protease family member and uses therefor
WO2002068464A3 (de) Fusionsprotein zum blocken des hiv nef-proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties